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Abstract The role of CpG methylation in the regulation of
tissue-specific gene expression is highly controversial. Cyclin A1
is a tissue-specifically expressed gene that is strongly methylated
in non-expressing tumor cell lines. We have established a novel
real-time PCR method to quantitate genomic CpG methylation
of the cyclin A1 promoter. Genomic DNA samples from different
human organs were treated with bisulfite and amplified with
methylation-specific primers and with primers amplifying
methylated as well as non-methylated DNA. PCR product
quantitation was obtained by using a fluorogenic probe labeled
with FAM and TAMRA. These analyses demonstrated that the
human cyclin A1 promoter was methylated in kidney, colon,
spleen, testis, and small intestine, but not in brain, liver,
pancreas, or heart. Expression of cyclin A1 was predominantly
found in testis. Low level expression of cyclin A1 was present in
spleen, prostate, leukocytes, colon, and thymus. Taken together,
our data provide evidence that CpG methylation patterns of the
human cyclin A1 promoter in human organs do not generally
correlate with cyclin A1 gene expression in vivo. ß 2001 Fed-
eration of European Biochemical Societies. Published by Else-
vier Science B.V. All rights reserved.
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1. Introduction
The tight control of gene expression is of fundamental im-
portance for the development of higher organisms. Several
layers of regulation are known that coordinate the correct
spatial and temporal regulation of gene expression [1]. Meth-
ylation of CpG dinucleotides in genomic DNA is a phenom-
enon that has long been known in mammals and may provide
a layer of epigenetic information [2].
In general, most of the human genome is methylated at
CpG dinucleotides, but transcriptionally active promoters in
CpG islands are usually non-methylated. Consequently, close
correlations between methylation and repressed transcription
on one hand and between non-methylation and active tran-
scription on the other hand exist for several genes [3,4]. These
¢ndings and others have prompted investigators to speculate
that CpG methylation itself is actively involved in transcrip-
tional regulation [2]. While the association between methyla-
tion and transcriptional repression appears to be strong in
tumor cells [5], the role of CpG methylation in normal devel-
opment and tissue-speci¢c gene expression is highly contro-
versial [6]. To date, most data deal with cell culture models,
but data on CpG methylation patterns in di¡erent human
organs exist so far only for few genes.
Recently, we have shown that the promoter of the human
cyclin A1 gene is heavily methylated in non-expressing solid
tumor cell lines [7]. No methylation of the cyclin A1 promoter
was found in cyclin A1-expressing cell lines derived from
acute myeloid leukemia. In addition, we were able to demon-
strate that a transgenic cyclin A1 promoter in mice directed
GFP expression in the testis independent of the methylation
status [7].
In the current study we developed a novel method to quan-
titate CpG methylation and used it for the analyses of the
endogenous cyclin A1 promoter in di¡erent human organs.
A signi¢cant degree of cyclin A1 promoter CpG methylation
was found in kidney, colon, spleen, testis, and small intestine,
whereas CpG methylation was absent in most other organs.
The methylation status of the cyclin A1 promoter in human
organs did not correlate with cyclin A1 mRNA expression as
shown by quantitative real-time RT-PCR. These data provide
evidence that CpG methylation is unlikely to be involved in
directing tissue-speci¢c expression of cyclin A1.
2. Materials and methods
2.1. Materials
HeLa cells and U937 monocytic leukemia cells were cultured in
Dulbecco’s modi¢ed Eagle’s medium and RPMI medium, respec-
tively. All media were supplemented with 10% fetal calf serum and
streptomycin and penicillin. Genomic DNA was extracted from or-
gans obtained in the pathology department at the time of autopsy.
Human cDNA derived from the di¡erent organs was purchased from
Clontech. These cDNAs represent RNA derived independently from
several persons.
2.2. Detection of CpG methylation
Genomic DNA was extracted using DNAzol (Gibco Life Technol-
ogy). Subsequently, the DNA was treated with bisul¢te as described
[7]. Methylation-speci¢c primers (5P to 3P : forward: CGT ACG TTT
GTC GCG GTC G, reverse: GAC TAA ACT ACC CAC CCG CG)
were designed that were speci¢c for methylated cyclin A1 promoter
sequences (MSP). A second set of primers was used that ampli¢ed
bisul¢te-treated non-methylated cyclin A1 promoter DNA (5P to 3P :
forward: TGG AGA GTG TAT GTT TGT TGT GGT TG, reverse:
AAA CTT AAC AAT ACA ACT AAA CTA CCC ACC C). To
amplify DNA sequences irrespective of their methylation status, equal
amounts of both sets of primers were mixed (All). In addition to the
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primers, a probe was designed that could bind to the bisul¢te-treated
DNA irrespective of the methylation status (5P to 3P : ACR CCC CCR
AAC CTA ACR AAA ACR TTT CCA). This probe was labeled with
FAM at the 5P end and with the quencher TAMRA at the 3P end. The
quencher molecule inhibited 5P FAM £uorescence when the probe was
intact. During the ampli¢cation of the PCR products, the probe an-
nealed to the antisense strand and the 5P exonuclease activity of the
Taq polymerase freed the £uorescent molecule. The resulting £uores-
cence was analyzed during each cycle and the cycle in which a sig-
ni¢cant increase of the £uorescence could be noted was determined as
the threshold cycle. Because of the exponential nature of PCR, the
degree of CpG methylation was calculated according to the formula:
fraction of methylated molecules 
2 threshold nonÿ specific primers minus threshold methylationÿ
specific primers
All PCR reactions were performed at least three times. The means
of the threshold values were used for the ¢nal calculation.
2.3. Quantitation of human cyclin A1 expression
Cyclin A1 expression was determined by quantitative real-time RT-
PCR. The cDNA was ampli¢ed in a SDS7700 sequencing detector
(PE Biosystems) using cyclin A1-speci¢c primers and a Taqman probe
(for primer sequence information see [7]). The probe was FAM-la-
beled at the 5P end and labeled with TAMRA at the 3P end. The
5P exonuclease activity of the Taq polymerase released the FAM mol-
ecule and led to an increase in £uorescence which was analyzed by the
SDS7700 during each PCR cycle. A standard curve derived from
serial dilutions of U937 cell line cDNA was used to obtain relative
quantitation data. These data were standardized using expression data
of GAPDH mRNA which was also analyzed by the 5P nuclease assay
[7]. The GAPDH probe was VIC-labeled at the 5P terminus. Relative
GAPDH expression was also quantitated using a standard curve
which was run on every plate that was analyzed. Cyclin A1 expression
data were then calculated by dividing the relative concentrations of
cyclin A1 by the GAPDH values.
3. Results
To quantitate methylation of the human cyclin A1 pro-
moter in healthy organs, we developed a new method, which
is based on real-time PCR ampli¢cation of bisul¢te-treated
DNA. Bisul¢te exposure of genomic DNA led to a change
of cytidine to uracil if the cytosine was not methylated. Meth-
ylated cytosine remained unchanged. Primers were designed
that either speci¢cally ampli¢ed methylated cyclin A1 pro-
moter sequences (MSP) or were able to amplify methylated
as well as non-methylated sequences (All) (Fig. 1). All primers
were speci¢c for bisul¢te-modi¢ed DNA and did not amplify
primary genomic DNA. In between the primer pairs, we de-
signed a £uorogenic probe that could bind to methylated as
well as to non-methylated sequences. Consequently, ampli¢-
cation by either primer pair led to the generation of £uores-
cence that was analyzed by the laser detector. Comparisons of
the threshold cycle (the PCR cycle when a signi¢cant increase
of £uorescence was observed for the ¢rst time) allowed the
calculation of the fraction of methylated DNA sequences (for
details see Section 2).
We initially tested this method on two cell lines with well-
known methylation patterns of the cyclin A1 promoter (Fig.
2). In HeLa cells, most of the sequences were methylated.
Consequently, no di¡erence in the threshold cycle was ob-
served when bisul¢te-exposed DNA was ampli¢ed by either
methylation-speci¢c primers (MSP) or primers amplifying all
sequences (All). In contrast, almost no methylation of the
human cyclin A1 promoter existed in strongly cyclin A1-ex-
pressing U937 leukemic cells. While the methylation non-spe-
ci¢c primers ampli¢ed bisul¢te-treated U937 cell DNA similar
to HeLa cell DNA, the methylation-speci¢c primers did not
amplify the DNA derived from U937 cells, indicating the
absence of genomic methylation.
Next, we focused on methylation of the cyclin A1 promoter
in di¡erent human organs. About 40% of the cyclin A1 pro-
moter sequences in the kidney were found to be methylated. A
Fig. 1. Novel real-time PCR-based assay for rapid analysis of CpG
methylation. DNA was isolated and bisul¢te-treated (for details see
Section 2). In the real-time quantitative PCR reaction, methylation-
speci¢c primers only bound to methylated DNA and did not anneal
to non-methylated DNA. Consequently, Taq polymerase only am-
pli¢ed methylated DNA and cleaved the annealed probe through its
exonuclease activity, thereby setting free the £uorogenic probe
FAM. With non-methylated DNA, the probe stayed intact and
TAMRA quenched the £uorescence of FAM. The methylation non-
speci¢c primers ampli¢ed both kinds of DNA, resulting in a signal
indicating the total amount of cyclin A1 promoter sequences in the
sample.
Fig. 2. Analyses of cyclin A1 promoter methylation status in cell
lines. Quantitative analyses of the methylation status of the cyclin
A1 promoter in the cell lines HeLa and U937 are shown. Bisul¢te-
treated DNA was ampli¢ed with primers speci¢c for methylation
(MSP) and primers amplifying the sequences irrespective of their
methylation status (All). On the x-axis the number of PCR cycles is
shown, on the y-axis the di¡erence between measured £uorescence
and the baseline (vRn). The threshold line is indicated as well.
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signi¢cant fraction of methylated sequences was also found in
spleen, testis, colon, and small intestine. No signi¢cant degree
of methylation was observed in brain, heart, liver, or pancreas
(Fig. 3). To correlate these ¢ndings with cyclin A1 gene ex-
pression, we performed quantitative real-time RT-PCR on
human cDNA samples derived from di¡erent human organs
(Fig. 4). These analyses con¢rmed that high levels of cyclin A1
expression were restricted to the testis. Low level expression
was detected in leukocytes, colon, and spleen. No signi¢cant
cyclin A1 expression was found in kidney, brain, small intes-
tine, heart, liver, pancreas, and muscle. Our ¢ndings provide
strong evidence that methylation of the cyclin A1 promoter is
not involved in directing tissue-speci¢c cyclin A1 expression in
humans. Cyclin A1 expression was found to be repressed in
several organs where no signi¢cant degree of cyclin A1 pro-
moter methylation was present, e.g. in brain or heart. Never-
theless, methylation of the cyclin A1 promoter was found in
some organs, e.g. kidney, where cyclin A1 expression was
notably absent.
4. Discussion
The role of genomic CpG methylation in the regulation of
gene expression in mammals is highly controversial. In the
current study, we established a new methodology that allows
rapid analyses of the methylation status of a single gene in
many samples. In addition, we show evidence for cyclin A1
promoter methylation in some human organs in vivo. Finally,
methylation of the cyclin A1 promoter did not correlate with
cyclin A1 gene expression in vivo as determined by quantita-
tive real-time RT-PCR.
Recently, several methods have been introduced that allow
analyses of the methylation status of small amounts of DNA.
These methods are based on the conversion of cytidine to
uracil following bisul¢te exposure and subsequent treatment
with sodium hydroxide [8]. Methylation of CpG dinucleotides
inhibits this conversion and the di¡erent techniques aim to
visualize this di¡erence between methylated and non-methyl-
ated sequences.
Fig. 3. Analyses of cyclin A1 promoter methylation status in human organs. The methylation status of the cyclin A1 promoter was analyzed in
samples of di¡erent human tissues. DNA was isolated, bisul¢te-treated, and ampli¢ed by real-time PCR techniques as described in Section 2.
The calculated fraction of methylated sequences in cyclin A1 promoter sequences is indicated. Each sample was independently analyzed at least
three times.
Fig. 4. Cyclin A1 expression in human organs. Expression levels of cyclin A1 were analyzed in a panel of di¡erent human cDNAs by real-time
quantitative PCR. Expression levels were standardized using expression of the housekeeping gene GAPDH.
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Methods that have been employed include PCR systems
with methylation-speci¢c primers [9]. An important drawback
of this method is the lack of any quantitative information.
Even when 99% of the sequences are non-methylated, meth-
ylation-speci¢c primers might produce a positive band. The
biological relevance of such a ¢nding appears to be doubtful.
More quantitative detection methods include single nucleotide
primer extension methods [10], or DNA sequencing [8]. All of
these methods are time-consuming, involve radioactivity, or
do not allow accurate estimation of the fraction of methylated
sequences.
Recently, a real-time PCR assay was published that used
three £uorogenic probes for quantitative analyses of CpG
methylation [11]. The method presented in our study uses
only one probe and is thus much more cost-e¡ective. In addi-
tion, the quality of probe labeling varies among di¡erent
probes and this phenomenon complicates the quantitation
when more than one probe is used. In our assay, the use of
the same probe for two di¡erent primer pairs circumvents
these problems.
Analyses of cyclin A1 promoter methylation in human or-
gans revealed a signi¢cant degree of methylation in some or-
gans. But methylation of all genomic cyclin A1 sequences as
detected in HeLa cells was not observed. This ¢nding prob-
ably hints at the mixed background of cells obtained from
human organs compared to cell lines. In addition, signi¢cant
fractions of methylated cyclin A1 sequences were found in
only ¢ve out of nine organs analyzed.
Most of the organs where cyclin A1 promoter methylation
was found did not express cyclin A1 as shown by real-time
RT-PCR analyses. Interestingly, a small percentage of meth-
ylated cyclin A1 sequences was found in the testis, an organ
with very high levels of cyclin A1 expression in pachytene
spermatocytes. Since it is unknown which cell types were
methylated in vivo, we cannot draw conclusions on an asso-
ciation between methylation and non-expression in the testis.
Previously, we have demonstrated that methylation of a trans-
genic cyclin A1 promoter in mice did not prevent the pro-
moter from being active during spermatogenesis [7]. Another
interesting phenomenon concerns the high degree of methyl-
ation in kidney and spleen, two organs that also express no or
only low levels of cyclin A1. In the transgenic mouse model
aberrant activity of the cyclin A1 promoter was detected in
collecting duct and glomerulus cells from the kidney as well as
in some splenic B cells [7]. In contrast, no cyclin A1 promoter
activity was detected in the kidney or in the spleen when the
transgenic promoter was methylated, a situation recapitulated
in the human tissue studies in this paper.
Taken together, these ¢ndings indicate that CpG methyla-
tion might be necessary for appropriate transcriptional con-
trol in some organs and cell types. So far, physiological meth-
ylation patterns in di¡erent organs are known for only very
few genes. K-Actin is one gene that has been studied previ-
ously [12]. The authors described an association between CpG
methylation and transcriptional repression in some organs.
Appropriate repression in other organs occurred in the ab-
sence of CpG methylation. These ¢ndings are very similar
to the ¢ndings concerning the cyclin A1 promoter presented
in our study. Our data show evidence that the physiological
expression pattern of cyclin A1 can be obtained in most or-
gans in the absence of CpG methylation.
In conclusion, we established a novel, rapid, high-through-
put assay for quantitative analyses of genomic CpG methyla-
tion patterns. Our analyses of cyclin A1 promoter methylation
patterns demonstrate that a signi¢cant fraction of CpG dinu-
cleotides was methylated in some of the human organs. Ab-
sence of methylation was not usually associated with tran-
scriptional repression as shown by quantitative real-time
RT-PCR analyses.
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